Benitec Biopharma Inc.

Benitec Biopharma Inc. is a clinical-stage biotechnology company that develops genetic medicines. The company utilizes a therapeutic platform combining gene silencing with functional gene replacement delivered through viral vectors. Its primary product candidate is BB-301, an investigational gene therapy designed to treat oculopharyngeal muscular dystrophy, a chronic degenerative muscle disorder. The company aims to serve patients suffering from this condition. Additionally, it engages with larger biopharmaceutical firms as commercial partners through potential co-development collaborations and out-licensing agreements.

Benitec is headquartered in Hayward, California. The company does not own or operate manufacturing facilities, instead planning to use contract manufacturing organizations. Its clinical programs address a disease diagnosed in approximately 35 countries worldwide. In addition, the organization maintains active patent families and holds registered trademarks across international jurisdictions, including the United States, Australia, the United Kingdom, and the European Union.

Summary of the business section of Benitec Biopharma's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of June 30, 2026, we had 24 full-time employees, one of whom has an MD, PhD, eight have a PhD, four have a Master’s Degree, two have a biotechnology certificate, and one has an MBA, for a total of 13 with post-graduate degrees.”